Compugen Ltd. (CGEN) exhibits 87.3% gross margins and 85.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 3.2x enterprise multiple and 4.8% implied options volatility.
Sustained 87.3% gross profitability converts into 43.1% operating margin and 85.0% ROIC, outpacing sector cost of capital.
ROIC: 85.0% // GM: 87.3%YoY revenue trajectory of +161.1% paired with 16.24% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +161.1% // FCF YLD: 16.24%Altman Z-Score of 3.80 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.80 // F-SCORE: 7/9Trading at 5.5x trailing P/E (4.6x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 5.5x // EV/EBITDA: 3.2xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $1.98 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 48.6% net margins.
NET MARGIN: 48.6% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CGEN & activate live FRED threshold breach alerts.